J3285
J3285 – Injection, treprostinil, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 21 NDCs crosswalked per 1 MG $54.740/unit ASP+6%
📋 J3285 summary
J3285 is a HCPCS Level II J-code used to bill treprostinil, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3285: Remodulin*, Treprostinil, Remodulin
Code J3285
Billing unit 1 MG Payment limit $54.740/unit NDC-Crosswalk 21
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3285
DescriptorInjection, treprostinil, 1 mg
Billing unit1 MG
Payment limit / unit$54.740
Est. ASP / unit$51.642 est.
Mapped NDCs21
Data periodQ3 2026
Last updated2026-08-20
💊 About Treprostinil Injection DRUG GUIDE
Treprostinil injection is used to treat pulmonary arterial hypertension (PAH, WHO Group 1) — high blood pressure in the arteries that supply the lungs.
It works to reduce the symptoms that make exercise difficult.
Clinical studies included patients with moderate-to-severe PAH symptoms (NYHA Class II–IV) due to idiopathic or heritable PAH, PAH related to congenital heart defects, and PAH related to connective tissue diseases.It is also used for PAH patients who need to transition off epoprostenol — a related medication — to slow the worsening of their condition during that switch.
The risks and benefits of the transition should be carefully discussed with a specialist before starting.
Clinical overview from our editorial drug guide for Treprostinil Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$54.740
Est. ASP / unit
$51.642 est.
Est. after 2% sequester
$53.645
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, treprostinil, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2006-01-01
Date added2006-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3285 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3285 WITH EST. MEDICARE PAY
21 NDCs map to J3285. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($54.740/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00703-0666-01 | Treprostinil 20 mg/20mL INJECTION, SOLUTION | Teva | 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0666-... | 20 mg/20mL | 20 | $1,094.80 | — | ● Active | CMS + PDAC |
| 00703-0676-01 | Treprostinil 50 mg/20mL INJECTION, SOLUTION | Teva | 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0676-... | 50 mg/20mL | 50 | $2,737.00 | — | ● Active | CMS + PDAC |
| 00703-0686-01 | Treprostinil 100 mg/20mL INJECTION, SOLUTION | Teva | 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0686-... | 100 mg/20mL | 100 | $5,474.00 | — | ● Active | CMS + PDAC |
| 00703-0696-01 | Treprostinil 200 mg/20mL INJECTION, SOLUTION | Teva | 1 VIAL, MULTI-DOSE in 1 CARTON (0703-0696-... | 200 mg/20mL | 200 | $10,948.00 | — | ● Active | CMS + PDAC |
| 00781-3420-80 | Treprostinil 20 mg/20mL INJECTION | Sandoz | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3420-... | 20 mg/20mL | 20 | $1,094.80 | — | ● Active | CMS + PDAC |
| 00781-3425-80 | Treprostinil 50 mg/20mL INJECTION | Sandoz | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3425-... | 50 mg/20mL | 50 | $2,737.00 | — | ● Active | CMS + PDAC |
| 00781-3427-80 | Treprostinil 100 mg/20mL INJECTION | Sandoz | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3427-... | 100 mg/20mL | 100 | $5,474.00 | — | ● Active | CMS + PDAC |
| 00781-3430-80 | Treprostinil 200 mg/20mL INJECTION | Sandoz | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3430-... | 200 mg/20mL | 200 | $10,948.00 | — | ● Active | CMS + PDAC |
| 42023-0206-01 | Treprostinil Injection | Endo | — | — | 20 | $1,094.80 | — | — | CMS + PDAC |
| 42023-0207-01 | Treprostinil Injection | Endo | — | — | 50 | $2,737.00 | — | — | CMS + PDAC |
| 42023-0208-01 | Treprostinil Injection | Endo | — | — | 100 | $5,474.00 | — | — | CMS + PDAC |
| 42023-0209-01 | Treprostinil Injection | Endo | — | — | 200 | $10,948.00 | — | — | CMS + PDAC |
| 43598-0646-11 | Treprostinil 50 mg/20mL INJECTION, SOLUTION | Dr.Reddy's | 1 VIAL in 1 CARTON (43598-646-11) / 20 mL... | 50 mg/20mL | 50 | $2,737.00 | — | ● Active | CMS + PDAC |
| 43598-0647-11 | Treprostinil 100 mg/20mL INJECTION, SOLUTION | Dr.Reddy's | 1 VIAL in 1 CARTON (43598-647-11) / 20 mL... | 100 mg/20mL | 100 | $5,474.00 | — | ● Active | CMS + PDAC |
| 43598-0648-11 | Treprostinil 200 mg/20mL INJECTION, SOLUTION | Dr.Reddy's | 1 VIAL in 1 CARTON (43598-648-11) / 20 mL... | 200 mg/20mL | 200 | $10,948.00 | — | ● Active | CMS + PDAC |
| 43598-0649-11 | Treprostinil 20 mg/20mL INJECTION, SOLUTION | Dr.Reddy's | 1 VIAL in 1 CARTON (43598-649-11) / 20 mL... | 20 mg/20mL | 20 | $1,094.80 | — | ● Active | CMS + PDAC |
| 66302-0101-01 | Remodulin treprostinil 20 mg/20mL INJECTION, SOLUTION | United | 1 VIAL in 1 BOX (66302-101-01) / 20 mL in... | 20 mg/20mL | 20 | $1,094.80 | — | ● Active | CMS + PDAC |
| 66302-0102-01 | Remodulin treprostinil 50 mg/20mL INJECTION, SOLUTION | United | 1 VIAL in 1 BOX (66302-102-01) / 20 mL in... | 50 mg/20mL | 50 | $2,737.00 | — | ● Active | CMS + PDAC |
| 66302-0105-01 | Remodulin treprostinil 100 mg/20mL INJECTION, SOLUTION | United | 1 VIAL in 1 BOX (66302-105-01) / 20 mL in... | 100 mg/20mL | 100 | $5,474.00 | — | ● Active | CMS + PDAC |
| 66302-0110-01 | Remodulin treprostinil 200 mg/20mL INJECTION, SOLUTION | United | 1 VIAL in 1 BOX (66302-110-01) / 20 mL in... | 200 mg/20mL | 200 | $10,948.00 | — | ● Active | CMS + PDAC |
| 66302-0114-01 | Remodulin treprostinil 8 mg/20mL INJECTION, SOLUTION | United | 1 VIAL in 1 BOX (66302-114-01) / 20 mL in... | 8 mg/20mL | 8 | $437.92 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$22.85M
Claims
2,534
Beneficiaries
631
Spend / beneficiary
$36,214.09
Spend / claim
$9,017.79
Trend by period
Where J3285 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #117 of 824
#112
MNEXSPIKE (12Y UP) 91323
$25.16M
#113
KIMMTRAK J9274
$24.06M
#114
PANZYGA J1576
$23.9M
#115
MVASI Q5107
$23.53M
#116
SAPHNELO J0491
$23.21M
#117
REMODULIN* J3285
$22.85M
#118
ANKTIVA J9028
$22.83M
#119
DARZALEX J9145
$22.67M
#120
ONIVYDE J9205
$22.24M
#121
EPKINLY J9321
$21.11M
#122
SARCLISA J9227
$21.08M
Total claims — #286 of 824
#281
IDOSE TR J7355
2,681
#282
DARZALEX J9145
2,647
#283
KRYSTEXXA J2507
2,633
#284
EOVIST A9581
2,602
#285
COMPLETE FT PER SQ C... Q4271
2,572
#286
REMODULIN* J3285
2,534
#287
SKYRIZI J2327
2,523
#288
QUTENZA J7336
2,519
#289
CYCLOPHOSPHAMIDE(J90... J9072
2,490
#290
AFLURIA (90658)* 90658
2,467
#291
CAMCEVI J1952
2,453
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $22.85M | 631 | 2,534 | $36,214.09 | $9,017.79 |
| 2025 (Q1-Q4) | $111.15M | 841 | 11,818 | $132,162.33 | $9,405.02 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$112.5M
Medicare paid
$88.03M
Submitted services
2,089,317
Denial rate
3.4%
Allowed / service
$55.76
Submitted charges
$248.74M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J3285
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
21 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3285 billing FAQ
What is HCPCS code J3285?
J3285 is a HCPCS Level II J-code used to bill Injection, treprostinil, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J3285?
One unit of J3285 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J3285 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J3285?
The Medicare Part B payment limit is $54.740 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $53.645 per unit. Payment limits are revised quarterly.
Which NDCs bill under J3285?
21 NDCs currently map to J3285 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3285 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.